← Leaderboards
Scott McNear Thacher
Orphagen Pharmaceuticals
$9,190,724
Attributed
$9,190,724
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,190,724 · 17
By mechanism
R44$4,877,130 · 3
R43$4,174,344 · 12
R21$70,000 · 1
R03$69,250 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeNuclear ReceptorsTranscription FactorLigandsPharmaceutical PreparationsBaseIn VivoRetinoidsLeadReceptorOrphanGenetic TranscriptionFamilyNuclear Orphan ReceptorAffectSmall Business Innovation Research GrantRegulationResponseMediatingMemberThyroid GlandAdverse EffectsAnimal ModelPharmacology
Grant awards (27)
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$634,145
R44 · FY2025 · DK · contact PI
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$1,078,081
R44 · FY2024 · DK · contact PI
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$693,171
R44 · FY2022 · CA · contact PI
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$1,306,362
R44 · FY2021 · CA · contact PI
HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction$160,677
R43 · FY2016 · HL · contact PI
HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction$164,374
R43 · FY2015 · HL · contact PI
Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa$222,161
R43 · FY2014 · TR · contact PI
Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa$224,474
R43 · FY2013 · TR · contact PI
Neural Stem Cell-Selective Drug Target for Small Molecule Therapy of Brain Tumors$250,507
R43 · FY2012 · CA · contact PI
Inhibitor of Adrenal Steroid Synthesis for Cancer Treatment$120,331
R43 · FY2011 · CA · contact PI
Novel CNS Target for Sleep-Wake and Psychiatric Disorders$481,388
R44 · FY2010 · MH · contact PI
Inhibitor of Adrenal Steroid Synthesis for Cancer Treatment$400,027
R43 · FY2010 · CA · contact PI
Novel CNS Target for Sleep-Wake and Psychiatric Disorders$204,192
R44 · FY2010 · MH · contact PI
Novel CNS Target for Sleep-Wake and Psychiatric Disorders$479,791
R44 · FY2009 · MH · contact PI
Small Molecule Inhibitors of Effector Th-17 Cells in Inflammatory Bowel Disease$266,559
R43 · FY2008 · DK · contact PI
Feasibility Study of Novel Drug Target for Multiple Sclerosis$210,190
R43 · FY2008 · NS · contact PI
Feasibility Study of Novel Drug Target for Multiple Sclerosis$303,596
R43 · FY2007 · NS · contact PI
Small molecule target for suppression of autoimmunity in rheumatoid arthritis$258,166
R43 · FY2007 · AR · contact PI
Small Molecule Ligand Discovery for Sleep Cycle Disorders$226,768
R43 · FY2006 · MH · contact PI
Small Molecule Screen for Circadian and Metabolic Transcription Factors$70,000
R21 · FY2006 · NS · contact PI
Small Molecule Ligand Discovery for Sleep Cycle Disorders$233,571
R43 · FY2005 · MH
Therapeutic Target for Atherogenic &Metabolic Syndromes$218,858
R43 · FY2005 · DK
Thymocyte Drug Target of Immune Reconstitution$270,181
R43 · FY2004 · AI
Adrenal Androgen Blockade for Metastic Prostate Cancer$249,846
R43 · FY2004 · CA
Small Molecular Screen for Thymocyte Drug Target (RMI)$69,250
R03 · FY2004 · NS
Adrenal Androgen Blockade for Metastic Prostate Cancer$249,900
R43 · FY2003 · CA
Novel Drug Target for Bile and Cholesterol Metabolism$144,158
R43 · FY2003 · DK